Evidence map›Paper›PMID 34281383›Full record

SynthesisStroke2021

Association of Oral Anticoagulation With Stroke in Atrial Fibrillation or Heart Failure: A Comparative Meta-Analysis.

Catriona Reddin, Conor Judge, Elaine Loughlin, Robert Murphy, Maria Costello, Alberto Alvarez, John Ferguson, Andrew Smyth, Michelle Canavan, Martin J O'Donnell

Open access · hybridAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Stroke, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Observational
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Catriona ReddinHRB-Clinical Research Facility (C.R., C.J., E.L., R.M., M. Costello, A.A., J.F., A.S., M. Canavan, M.J.O.), National University of Ireland Galway.ORCID 0000-0002-6396-5913
Conor JudgeHRB-Clinical Research Facility (C.R., C.J., E.L., R.M., M. Costello, A.A., J.F., A.S., M. Canavan, M.J.O.), National University of Ireland Galway.ORCID 0000-0001-9473-2920
Elaine LoughlinHRB-Clinical Research Facility (C.R., C.J., E.L., R.M., M. Costello, A.A., J.F., A.S., M. Canavan, M.J.O.), National University of Ireland Galway.
Robert MurphyHRB-Clinical Research Facility (C.R., C.J., E.L., R.M., M. Costello, A.A., J.F., A.S., M. Canavan, M.J.O.), National University of Ireland Galway.ORCID 0000-0001-5446-4175
Maria CostelloHRB-Clinical Research Facility (C.R., C.J., E.L., R.M., M. Costello, A.A., J.F., A.S., M. Canavan, M.J.O.), National University of Ireland Galway.ORCID 0000-0002-8305-6610
Alberto AlvarezHRB-Clinical Research Facility (C.R., C.J., E.L., R.M., M. Costello, A.A., J.F., A.S., M. Canavan, M.J.O.), National University of Ireland Galway.ORCID 0000-0001-5011-9008
John FergusonHRB-Clinical Research Facility (C.R., C.J., E.L., R.M., M. Costello, A.A., J.F., A.S., M. Canavan, M.J.O.), National University of Ireland Galway.
Andrew SmythHRB-Clinical Research Facility (C.R., C.J., E.L., R.M., M. Costello, A.A., J.F., A.S., M. Canavan, M.J.O.), National University of Ireland Galway.ORCID 0000-0002-3320-8292
Michelle CanavanHRB-Clinical Research Facility (C.R., C.J., E.L., R.M., M. Costello, A.A., J.F., A.S., M. Canavan, M.J.O.), National University of Ireland Galway.
Martin J O'DonnellHRB-Clinical Research Facility (C.R., C.J., E.L., R.M., M. Costello, A.A., J.F., A.S., M. Canavan, M.J.O.), National University of Ireland Galway.
National University of Ireland · IEOllscoil na Gaillimhe – University of Galway · IE

Funding

European Research Council 640580Wellcome Trust 203930
6 · The paper itself

Abstract

Background and Purpose: Atrial fibrillation and heart failure with reduced ejection fraction (HFrEF) are common sources of cardioembolism. While oral anticoagulation is strongly recommended for atrial fibrillation, there are marked variations in guideline recommendations for HFrEF due to uncertainty about net clinical benefit. This systematic review and meta-analysis evaluates the comparative association of oral anticoagulation with stroke and other cardiovascular risk in populations with atrial fibrillation or HFrEF in sinus rhythm and identify factors mediating different estimates of net clinical benefit. Methods: PubMed and Embase were searched from database inception to November 20, 2019 for randomized clinical trials comparing oral anticoagulation to control. A random-effects meta-analysis was used to estimate a pooled treatment-effect overall and within atrial fibrillation and HFrEF trials. Differences in treatment effect were assessed by estimating I2 among all trials and testing the between-trial-population P-interaction. The primary outcome measure was all stroke. Secondary outcome measures were ischemic stroke, hemorrhagic stroke, mortality, myocardial infarction, and major hemorrhage. Results: Twenty-one trials were eligible for inclusion, 15 (n=19 332) in atrial fibrillation (mean follow-up: 23.1 months), and 6 (n=9866) in HFrEF (mean follow-up: 23.9 months). There were differences in primary outcomes between trial populations, with all-cause mortality included for 95.2% of HFrEF trial population versus 0.38% for atrial fibrillation. Mortality was higher in controls groups of HFrEF populations (19.0% versus 9.6%) but rates of stroke lower (3.1% versus 7.0%) compared with atrial fibrillation. The association of oral anticoagulation with all stroke was consistent for atrial fibrillation (odds ratio, 0.51 [95% CI, 0.42–0.63]) and HFrEF (odds ratio, 0.61 [95% CI, 0.47–0.79]; I2=12.4%; P interaction=0.31). There were no statistically significant differences in the association of oral anticoagulation with cardiovascular events, mortality or bleeding between populations. Conclusions: The relative association of oral anticoagulation with stroke risk, and other cardiovascular outcomes, is similar for patients with atrial fibrillation and HFrEF. Differences in the primary outcomes employed by trials in HFrEF, compared with atrial fibrillation, may have contributed to differing conclusions of the relative efficacy of oral anticoagulation.

Indexed as

AnticoagulantsAtrial FibrillationHeart FailureHumansStrokeStroke VolumeAnticoagulantsanticoagulantsatrial fibrillationheart failureodds ratiouncertainty

Identifiers

PMID34281383
PMCPMC8478106
OpenAlexW3184478206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.